Peer review reports
From: A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
| Original Submission |
| 29 Mar 2023 |
Submitted |
Original manuscript
|
| Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
| Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
| 24 Oct 2023 |
Reviewed |
Reviewer Report
|
| 15 Jul 2024 |
Reviewed |
Reviewer Report
|
| 21 Aug 2024 |
Author responded |
Author comments - Zhimin Shao
|
| Resubmission - Version 4 |
| 21 Aug 2024 |
Submitted |
Manuscript version 4
|
| 29 Aug 2024 |
Reviewed |
Reviewer Report
|
| 2 Sep 2024 |
Reviewed |
Reviewer Report
|
| Resubmission - Version 5 |
|
Submitted |
Manuscript version 5
|
| Publishing |
| 3 Sep 2024 |
Editorially accepted |
|
| 13 Sep 2024 |
Article published |
10.1186/s12885-024-12892-5
|
Learn about peer review
